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Osteosarcoma is a kind of bone cancer mainly affecting children and young adults and is lethal 
in about a third of cases. The treatment of osteosarcoma has evolved greatly during the last 40 
years, however, the great progress that was seen in the 1970s and early 1980s has since 
stalled. The main challenge now is that advanced combination treatment can’t continue prolong 
the survival. Based on the micro-metastatic disease related to shorter survival, biologic 
response modifiers become a new treatment which can stimulate the immune system to 
eradicate minimal residual disease post-surgery, chemotherapy and radiotherapy.  This kind 
immune treatment may improve the disease-free and long-term survival rates of patients. 
Mifamurtide is a novel biologic response modifier which is indicated for the treatment of high-
grade, non-metastasizing, resectable osteosarcoma following complete surgical removal in 
children, adolescents, and young adults. In our study, we searched for non-phase l Mifamurtide 
clinical studies on osteosarcoma through Medline, Google Scholar, and Clinical Trial 
Government Database. Among six clinical studies we found, two phase ll trials, one phase lll 
trial, one patient-access study, one decision study, and one cohort study. We systematically 
analyzed these studies and further evaluated the efficacy, side effects and safety of Mifamurtide 
on osteosarcoma. 
  
